ERIS Lifescience

ERISLIFESCIENCES28 Mar 2024
Pharmaceuticals
+2.35 (+0.28%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in ERIS Lifescience
ERIS Lifescience
Pharmaceuticals
ERISLIFESCIENCES28 Mar 2024
+2.35 (+0.28%)
OverviewFundamentals
1D
1M
6M
1Y
5Y
All

ERIS Lifescience - Share Price & Details

Lowest Today
832
Highest Today
862.15
Today’s Open
848
Prev. Close
841
52 Week High
971.9
52 Week Low
566.3
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
47.08%
Upper Circuit
Lower Circuit
P/E TTM
32.87
P/B Ratio
4.67
Traded Value(Cr)
0.00
EPS TTM
25.59
Book value
Dividend
0.87%

Price Performance

0.04 %
1 Wk
-3.32 %
1 M
-7.17 %
3 M
47.08 %
1 Y
-6.89 %
YTD

Traded Volume Movement

Technical Details

Support 3
800
Support 2
816
Support 1
830
Pivot Point :
846
Resistance 1
860
Resistance 2
876
Resistance 3
890

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
ERIS Lifesciences Ltd
₹843.35(+2.35/0.28%)
843.35+2.3511,471.9447.0832.874.67
Lupin Ltd
₹1,616.80(+16.85/1.05%)
1,616.80+16.8573,665.75150.9035.773.82
J B Chemicals & Pharmaceuticals Ltd
₹1,650.40(+7.50/0.46%)
1,650.40+7.5025,613.3568.3950.579.54
Ipca Laboratories Ltd
₹1,237.40(+32.10/2.66%)
1,237.40+32.1031,393.3656.3357.065.06
Sanofi India Ltd
₹8,113.95(+153.15/1.92%)
8,113.95+153.1518,686.4344.1831.6618.41
361.45+0.652,121.9130.1812.301.34

About ERIS Lifesciences Ltd

ERIS Lifesciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 11442.7 crores. It has reported a sales of Rs. 315.96 crores and a net profit of Rs. 31.66 crores for the quarter ended December 2018. The company management includes Amit Indubhushan Bakshi, Amit Indubhushan Bakshi,Kaushal Kamlesh Shah,Inderjeet Singh Negi,Krishnakumar Vaidyanathan,Sujesh Vasudevan,Prashant Gupta,Rajeev Narotam Dalal,Kalpana Unadkat (ERIS Lifesciences Ltd) among others.
Chairman
Amit Indubhushan Bakshi
Registered office
8th Floor Commerce House -IV,Prahladnagar 100 FT Road,Ahmedabad,Gujarat,380015
FAX :91-79-48903474
Background
Incorporation Year2007
Face Value₹1
Market Lot1

Latest News

Stupendous FY24 drives market cap of 25 cos by Rs 1 lakh crore
A stellar run by domestic equities in FY24 saw the market capitalization of 25 companies rise by atleast Rs 1 lakh crore in a year. Of this, 17 of them are part of benchmark Nifty 50.The Nifty has gained nearly 29% in FY24 and it also tested a lifetime high after a muted show in FY23.Robust corporate earnings, high capital investments by the government, strong domestic economic growth.
29 Mar 2024 | 11:43 AM
Buy or sell: Rajesh Palviya of Axis Securities recommends to buy, hold?
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, finished Thursday's session—the final trading day of the fiscal year 2024—with strong gains amidst favourable global cues. Nifty 50 zoomed around 30% in FY24, and Sensex surged about 28% in the same period. On Thursday, the 30-share BSE Sensex closed higher by 655.04 points or 0.90% at 73,651.35 level.
29 Mar 2024 | 11:02 AM
Short-term picks: Three stocks that may generate 17-25% returns
The Nifty 50 index has consistently displayed a bullish price structure, characterised by higher top, higher bottom formations, and is hovering near its all-time high levels on the monthly charts, indicating a strong positive sentiment for the long term. Recently, the index found significant support at the 13-week EMA (exponential moving average) and formed a notable Bullish Opening.
29 Mar 2024 | 10:01 AM
Three stocks to bet on for 17-25% return as bulls may rule Nifty
The Nifty 50 index has consistently displayed a bullish price structure, characterised by higher top, higher bottom formations, and is hovering near its all-time high levels on the monthly charts, indicating a strong positive sentiment for the long term. Recently, the index found significant support at the 13-week EMA (exponential moving average) and formed a notable Bullish Opening.
29 Mar 2024 | 11:07 AM
Buy or sell: Rajesh Palviya of Axis Securities recommends to buy, hold?
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, finished Thursday's session—the final trading day of the fiscal year 2024—with strong gains amidst favourable global cues. Nifty 50 zoomed around 30% in FY24, and Sensex surged about 28% in the same period. On Thursday, the 30-share BSE Sensex closed higher by 655.04 points or 0.90% at 73,651.35 level.
29 Mar 2024 | 11:02 AM

How to buy ERIS Lifescience shares on nse?

To buy ERIS Lifescience shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the ERIS Lifescience share price today?

The ERIS Lifescience shares price on nse is Rs.843.35 today.

What is the market cap of ERIS Lifescience shares on NSE ?

The company has a market capitalization of Rs.11471.94Cr

What is the PE & PB ratio of ERIS Lifescience shares ?

PE is 32.87 and PB is 4.67

What is the 52 Week High and Low of ERIS Lifescience shares?

ERIS Lifescience stock price high: Rs.971.9 ERIS Lifescience stock price low: Rs.566.3

What is the price of ERIS Life Sciences stocks on BSE?

The price of ERIS Life Sciences as of the end of day 17th April 2023 was INR 612.6 on BSE.

Is it safe to buy ERIS Life Sciences?

ERIS Life Sciences net profit has increased from Rs. 291.15 crores to Rs. 405.79 crores in the last four years. And the company's sales revenue has grown from Rs.982.6 crores to Rs. 1347 crores in the last four years. 

ERIS Life Sciences stock 52 weeks low is Rs.551.3 and high is Rs.749.8.

Equity investment is a risk like any other investment and it is advisable to take professional advice before investing.  

 

What is the current market value per stock of ERIS Life Sciences?

The current market value (or market capitalization) of ERIS Life Sciences is approximately Rs. 8.33K crores as on 17th April 2023.

Does ERIS Life Science have any debts?

ERIS Life Sciences has a debt-to-equity ratio of 0.13.  

 

Will ERIS Life Science stock price increase?

Eris Life Sciences is a pharmaceutical company based in India that focuses on developing, manufacturing, and marketing branded pharmaceutical products across various therapeutic areas. The company's products are sold in India and other countries, including Nepal, Sri Lanka, and Mauritius.

However, it is near impossible to predict the future movements of stock prices, as they are linked to a wide range of variables, including market trends, economic conditions, company performance, and global events.

It's imperative to conduct thorough research and due diligence in making any investment decisions. And to consider several relevant factors that could impact the company's future prospects.

 

Should I buy or sell ERIS Life Science?

ERIS Life Sciences stock has given a positive return of 33.61%  over the last 3 years and a negative return of -12.85% over the past 12 months.  

Selling or buying of specific stock or stocks depends on your personal financial goals and risk tolerance. 

 

setTimeout(function() { }, 5000);